rosiglitazone has been researched along with fenofibric acid in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 11 (64.71) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL | 1 |
| Albrektsen, T; Bury, PS; Deussen, HJ; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wulff, EM; Ynddal, L | 1 |
| Agejas, J; Alt, CA; Ardecky, R; Briere, DA; Brooks, DA; Brozinick, JT; Dolores Martín-Ortega, M; Ferritto, R; Fraser, JD; González, R; Hawkins, E; Lamas, C; López de Uralde, B; Martín, JA; Misener, EA; Montrose-Rafizadeh, C; Parra, F; Prieto, L; Reifel-Miller, A; Rhodes, GA; Rizzo, JR; Robey, RL; Rojo, I; Torrado, A; Warshawsky, AM; Wendel, SR; Zhang, TY | 1 |
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Berger, JP; Doebber, TW; Forrest, MJ; Jones, AB; Liu, K; Macnaul, KL; Moller, DE; Xu, L; Zhou, G | 1 |
| Ajamie, RT; Briere, DA; Brozinick, JT; Devanarayan, V; Hawkins, ED; Henry, JR; Li, Y; Misener, EA; Montrose-Rafizadeh, C; Warshawsky, AM; Wilken, B; Yumibe, NP; Zink, RW | 1 |
| Alt, CA; Brozinick, JT; Harkness, AR; Hawkins, ED; Henry, JR; Matthews, DP; Miller, AR; Misener, EA; Montrose-Rafizadeh, C; Rhodes, GA; Shen, Q; Udodong, UE; Vance, JA; Wang, M; Warshawsky, AM; Zhang, TY; Zink, RW | 1 |
| Daugaard, JR; Fleckner, J; Galsgaard, ED; Havranek, M; Jeppesen, CB; Jeppesen, L; Mogensen, JP; Olsen, GS; Panajotova, V; Pettersson, I; Pihera, P; Polivka, Z; Sauerberg, P; Wulff, EM; Ynddal, L | 1 |
| Bénardeau, A; Benz, J; Binggeli, A; Blum, D; Boehringer, M; Grether, U; Hilpert, H; Kuhn, B; Märki, HP; Meyer, M; Mohr, P; Püntener, K; Raab, S; Ruf, A; Schlatter, D | 1 |
| Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Bourne, PC; Dou, X; Duerfeldt, AS; Ma, JX; Nath, D; Nurmemmedov, E; Shin, H | 1 |
| Auwerx, J; Briggs, M; Deeb, S; Heyman, RA; Lefebvre, AM; Peinado-Onsurbe, J; Schoonjans, K; Staels, B | 1 |
| Andersson, Y; Fruchart, JC; Kosykh, V; Lefebvre, AM; Majd, Z; Martin, G; Najib, J; Sechkin, AV; Staels, B | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Benéteau, N; Chapuis, V; Colpaert, FC; Dupont-Passelaigue, E; Junquéro, D; Lestienne, F; Patoiseau, JF; Rival, Y; Taillandier, T | 1 |
2 review(s) available for rosiglitazone and fenofibric acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
15 other study(ies) available for rosiglitazone and fenofibric acid
| Article | Year |
|---|---|
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2001 |
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
Topics: Alkenes; Amino Acid Sequence; Animals; Binding Sites; Biological Availability; Cell Line; Crystallography, X-Ray; Dimerization; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Sequence Data; Propionates; Rats; Receptors, Cytoplasmic and Nuclear; Sequence Alignment; Stereoisomerism; Transcription Factors; Transcriptional Activation | 2003 |
2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.
Topics: Animals; Blood Glucose; Cinnamates; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Zucker; Structure-Activity Relationship; Triglycerides | 2005 |
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Carrier Proteins; Chlorocebus aethiops; Cholesterol; COS Cells; Diabetes Mellitus, Type 2; Dogs; Fatty Acid-Binding Proteins; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Isoxazoles; Mice; Mice, Obese; PPAR alpha; PPAR gamma; Propionates; Radioligand Assay; RNA, Messenger; Structure-Activity Relationship; Transcriptional Activation; Triglycerides; Weight Gain | 2005 |
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Topics: Animals; Blood Glucose; Humans; Hypoglycemic Agents; Mice; Models, Molecular; Peroxisome Proliferator-Activated Receptors; PPAR gamma; Rosiglitazone; Tetrahydroisoquinolines; Thiazolidinediones | 2006 |
Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.
Topics: Cinnamates; Humans; Hypoglycemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2006 |
Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.
Topics: Administration, Oral; Allyl Compounds; Animals; Apolipoprotein B-100; Binding Sites; Cell Line; Cholesterol Ester Transfer Proteins; Crystallography, X-Ray; Dietary Fats; Fatty Acids, Nonesterified; Female; Humans; Lipid Metabolism; Male; Mice; Mice, Transgenic; Models, Molecular; Muscle, Skeletal; Oxidation-Reduction; Phenylacetates; PPAR delta; Rats; Structure-Activity Relationship; Transcriptional Activation | 2007 |
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.
Topics: Animals; Chemistry, Pharmaceutical; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Drug Design; Dyslipidemias; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Thiophenes | 2009 |
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity | 2009 |
Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders.
Topics: Animals; Benzylamines; Capillary Permeability; Cell Line; Diabetic Retinopathy; Disease Models, Animal; Drug Design; Drug Discovery; Humans; PPAR alpha; Rats; Retinal Diseases; Streptozocin | 2020 |
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Cell Line; Dimerization; DNA; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Myocardium; Organ Specificity; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 1996 |
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
Topics: Aging; Animals; Apolipoprotein C-I; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Fenofibrate; Gene Expression Regulation; Gene Expression Regulation, Developmental; Humans; Hypolipidemic Agents; Kinetics; Liver; Male; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.
Topics: Acetamides; Acetates; Anilides; Cardiovascular Agents; Cell Line; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Macrophages; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mevalonic Acid; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tetradecanoylphorbol Acetate; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2004 |